Change Healthcare vs Superluminal Medicines

Side-by-side comparison of AI visibility scores, market position, and capabilities

Superluminal Medicines leads in AI visibility (86 vs 66)
Change Healthcare logo

Change Healthcare

ChallengerHealthcare

Revenue Cycle

Healthcare clearinghouse processing 15B+ annual claims acquired by Optum; 2024 ransomware attack caused $1B+ provider disruption and sparked nationwide healthcare cybersecurity overhaul.

AI VisibilityBeta
Overall Score
B66
Category Rank
#1 of 1
AI Consensus
55%
Trend
stable
Per Platform
ChatGPT
59
Perplexity
60
Gemini
58

About

Change Healthcare (now part of Optum) is a healthcare technology company providing claims processing, payment management, network intelligence, and clinical decision support tools to the US healthcare ecosystem — connecting payers, providers, pharmacies, and patients through data and technology infrastructure. Change Healthcare was acquired by UnitedHealth Group's Optum subsidiary in October 2022 following a lengthy regulatory review that included a DOJ lawsuit to block the acquisition on antitrust grounds.

Full profile
Superluminal Medicines logo

Superluminal Medicines

LeaderHealthcare

General

Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.

AI VisibilityBeta
Overall Score
A86
Category Rank
#85 of 1158
AI Consensus
59%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
80
Gemini
93

About

Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.

Full profile

AI Visibility Head-to-Head

66
Overall Score
86
#1
Category Rank
#85
55
AI Consensus
59
stable
Trend
stable
59
ChatGPT
83
60
Perplexity
80
58
Gemini
93
64
Claude
83
76
Grok
95

Key Details

Category
Revenue Cycle
General
Tier
Challenger
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Change Healthcare
Revenue Cycle

Integrations

Only Superluminal Medicines

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.